• Tuesday, September 4, 2018 @ 7:45 am

Clinerion, a real-world data solutions firm focusing on improving efficiency in clinical trials across geographies, and Patient iP, a health data and analytics company providing patient data insights to accelerate and transform clinical research within the United States, are partnering to improve clinical trial design, site selection and patient enrollment.

The companies will collaborate using Clinerion’s intelligent, patented Patient Network Explorer platform and Patient iP’s proprietary daTAscape asset to better target clinical trial sites and accelerate trial enrollment on a global scale. Clinerion aggregates healthcare information across institutions and geographies from their global network of partner hospitals, creating one single comprehensive real-time view. Clinerion’s network currently includes more than 17 million real time patient lives, with an additional 55 million lives contracted and in implementation, across more than 100 hospitals in the Americas, Europe and Asia. Used in combination with Patient iP’s platform which contains more than 16 million ambulatory electronic medical records (EMR) across 5,000 practice sites, the partnership will bring remarkable improvements to clinical trials.

“Patient iP and Clinerion, as alliance partners, are a partnership of providers providing similar services, with a complementary geographic footprint. The creation of a network of Clinerion alliance partners establishes a new, global and comprehensive, service resource for actionable patient data insights for clinical research,” says Ian Rentsch, CEO of Clinerion. “We are happy to bring the international footprint of our hospital network to the benefit of Patient iP’s clients. At the same time, this collaboration will broaden our current ability to service clients with real-world data from the USA. Our offerings complement each other well.”

“Patient iP is excited about the potential that a collaboration with Clinerion brings to the patient qualification space. Our combined focus on providing opportunities for the right patient at the right time creates a strength that is difficult to match,” said Michael Margiotta, Chairman, Founder and CEO of Patient iP. “Our complementary technologies and global reach will now enable both Patient iP and Clinerion to view patient populations from a much more diverse and inclusive perspective than we are able to do independently of each other and thus service our customers better than ever.”

You may also be interested in